Myria Biosciences

Executive Summary

Myria Biosciences is a private biotechnology company headquartered in Basel, Switzerland, with operations also in the UK. Founded in 2019, the company leverages artificial intelligence and machine learning to design novel microbes that produce therapies for unmet medical needs, focusing on the microbiome and chemical space exploration. By combining AI-driven microbial design with proprietary biosynthesis platforms, Myria aims to unlock new chemical entities that are difficult to access through traditional synthetic chemistry or natural product discovery. This approach positions the company at the intersection of synthetic biology, AI, and microbiome therapeutics, targeting indications where conventional small molecules or biologics have fallen short. As an early-stage private company, Myria has not disclosed significant funding rounds or pipeline details in public records. However, its location in the vibrant Basel biotech ecosystem and its focus on AI-enabled microbiome engineering suggest strong potential for innovation and partnerships. The company's ability to advance its technology toward preclinical and clinical validation will be critical. While still in a pre-revenue phase, Myria's unique value proposition could attract interest from larger pharma seeking novel modalities. The conviction score reflects the promising convergence of AI and microbiome science, tempered by the early stage and limited publicly available data.

Upcoming Catalysts (preview)

• Q2 2026Series A or B financing round to advance platform and pipeline70% success
• H2 2026Partnership or collaboration with a pharmaceutical company for microbiome-based therapeutics50% success
• Q4 2026Announcement of lead candidate nomination or preclinical proof-of-concept data60% success